Showing 1771-1780 of 1808 results for "".
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar
- CeraVe Launches Seven New Sunscreens with Barrier-Repairing Ceramideshttps://practicaldermatology.com/news/20130225-cerave_launches_seven_new_sunscreens_with_barrier-repairing_ceramides/2459609/Seven newCeraVe sunscreening products are now available in the Sun Protection aisle at drugstores and mass market retailers nationwide. The CeraVe Sun Care line, developed with dermatologists, includes products for the face and body with various applications offe
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- Free Skin Cancer Screenings January 26 in Southeasthttps://practicaldermatology.com/news/20130115-free_skin_cancer_screenings_january_26_in_southeast/2459636/Gulf Coast Dermatology will offer free full-body skin cancer screenings on Saturday, January 26 from 9 a.m. to noon at several of their locations. The screenings are provided by appointment only and are for new patients. Appointments for the
- Viscot Medical Introduces the AllSkin Plus+https://practicaldermatology.com/news/20130110-viscot_medical_introduces_the_allskin_plus/2459644/Viscot Medical released the AllSkin Plus+, a prep resistant ink marker that offers maximum visibility and prep resistance on all skin tones. According to the company, the VIXL brilliant blue ink provides enhanced visibility even after prepping with
- Promius Pharma, LLC Increases Sales Force by 50 Percenthttps://practicaldermatology.com/news/20130102-promius_pharma_llc_increases_sales_force_by_50_percent/2459650/Promius Pharma, LLC is expanding its sales force to 60 from 40. Promius Pharma, which markets clinical prescription products to the US dermatology community, is in growth mode according to Rob D'Urso, head of sales and marketing for the company. “Promius Pharma is gearing up for significant growth
- Galderma Acquires Spirighttps://practicaldermatology.com/news/20121213-galderma_acquires_spirig/2459659/Galderma Pharma S.A. and Spirig Pharma A.G. entered into a definitive agreement under which Galderma will acquire Spirig. Spirig's products treat conditions such as solar damage, skin barrier function impairment, and actinic keratosis. Leading br
- Court: Off-label Drug Promotion Is Protected Speechhttps://practicaldermatology.com/news/20121204-court_off-label_drug_promotion_is_protected_speech/2459665/The 2nd US Circuit Court of Appeals in New York voted 2-1 to overturn a pharmaceutical salesman's conviction for off-label drug marketing, citing violations against his free speech rights under the First Amendment. The ruling could threaten FDA rules that prevent the marketing of treatments for uses
- Picato Approved in European Unionhttps://practicaldermatology.com/news/20121119-picato_approved_in_european_union/2459677/The European Commission has granted marketing authorization for LEO Pharma's Picato (ingenol mebutate) gel for the treatment of actinic keratosis in the European Union (EU). Picato was approved in the US earlier this year.
- Sun Pharmaceutical to Buy DUSA Pharmaceuticalshttps://practicaldermatology.com/news/20121118-sun_pharmaceutical_to_buy_dusa_pharmaceuticals/2459678/Sun Pharmaceutical Industries Ltd. will buy DUSA Pharmaceuticals Inc. for about $215 million in cash, as the India-based company looks to make a foray into the lucrative market for dermatological treatments. The deal has been unanimously approved by the boards of both companies and DUSA's board has